These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37001946)

  • 81. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update.
    Hwang JP; Feld JJ; Hammond SP; Wang SH; Alston-Johnson DE; Cryer DR; Hershman DL; Loehrer AP; Sabichi AL; Symington BE; Terrault N; Wong ML; Somerfield MR; Artz AS
    J Clin Oncol; 2020 Nov; 38(31):3698-3715. PubMed ID: 32716741
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?
    Lampertico P; Viganò M; Colombo M
    Liver Int; 2013 Feb; 33 Suppl 1():157-63. PubMed ID: 23286860
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study.
    Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH
    J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102
    [TBL] [Abstract][Full Text] [Related]  

  • 84. HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy.
    Mak LY; Cloherty G; Wong DK; Gersch J; Seto WK; Fung J; Yuen MF
    Hepatology; 2021 Jun; 73(6):2167-2179. PubMed ID: 33159329
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation.
    Wu Y; Huang H; Luo Y
    Front Immunol; 2020; 11():610500. PubMed ID: 33613534
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data.
    El Kassas M; Shimakawa Y; Ali-Eldin Z; Funk AL; Wifi MN; Zaky S; El-Raey F; Esmat G; Fontanet A
    Liver Int; 2018 Dec; 38(12):2159-2169. PubMed ID: 29738637
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL.
    Tseng TN; Hu TH; Wang JH; Kuo YH; Hung CH; Lu SN; Jeng WJ; Chen CH
    Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2803-2812.e2. PubMed ID: 32360818
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study.
    Cao J; Chi H; Yu T; Li Z; Hansen BE; Zhang X; Zhong C; Sun J; Hou J; Janssen HLA; Peng J
    J Infect Dis; 2017 Feb; 215(4):581-589. PubMed ID: 28329347
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Management of psoriasis patients with hepatitis B or hepatitis C virus infection.
    Bonifati C; Lora V; Graceffa D; Nosotti L
    World J Gastroenterol; 2016 Jul; 22(28):6444-55. PubMed ID: 27605880
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy.
    Chi H; Li Z; Hansen BE; Yu T; Zhang X; Sun J; Hou J; Janssen HLA; Peng J
    Clin Gastroenterol Hepatol; 2019 Jan; 17(1):182-191.e1. PubMed ID: 29902645
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
    Hadziyannis SJ; Sevastianos V; Rapti I; Vassilopoulos D; Hadziyannis E
    Gastroenterology; 2012 Sep; 143(3):629-636.e1. PubMed ID: 22659218
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome.
    Wu D; Ning Q
    J Infect Dis; 2017 Nov; 216(suppl_8):S771-S777. PubMed ID: 29156046
    [TBL] [Abstract][Full Text] [Related]  

  • 93. HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis B.
    Yuen L; Revill PA; Rosenberg G; Wagner J; Littlejohn M; Bayliss J; Jackson K; Tan SK; Gaggar A; Kitrinos K; Subramanian M; Gane E; Chan HLY; Li X; Bowden S; Locarnini S; Thompson A
    J Viral Hepat; 2020 Oct; 27(10):1061-1070. PubMed ID: 32384174
    [TBL] [Abstract][Full Text] [Related]  

  • 94. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy.
    Burdette DL; Lazerwith S; Yang J; Chan HLY; Delaney Iv WE; Fletcher SP; Cihlar T; Feierbach B
    PLoS One; 2022; 17(4):e0262516. PubMed ID: 35363817
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Clinical relevance of the study of hepatitis B virus covalently closed circular DNA.
    Kumar R; Pérez-Del-Pulgar S; Testoni B; Lebossé F; Zoulim F
    Liver Int; 2016 Jan; 36 Suppl 1():72-7. PubMed ID: 26725901
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Is HBsAg quantification ready, for prime time?
    Chevaliez S
    Clin Res Hepatol Gastroenterol; 2013 Dec; 37(6):559-63. PubMed ID: 23932705
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies.
    Degasperi E; Anolli MP; Lampertico P
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366502
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver fibrosis: a study protocol.
    Zhu S; Wu L; Mei Y; Liu Z; Lin L; Yuan J; Li J; Li X; Peng L
    BMJ Open; 2021 Oct; 11(10):e049104. PubMed ID: 34697111
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration.
    Hunt CM; Beste LA; Lowy E; Suzuki A; Moylan CA; Tillmann HL; Ioannou GN; Lim JK; Kelley MJ; Provenzale D
    World J Gastroenterol; 2016 May; 22(19):4732-40. PubMed ID: 27217704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.